Actively Recruiting
Evaluation of the Effect of Vitamin E alpha-tocopherol Supplementation on Clinical Activity and Inflammation in Patients With Rheumatoid Arthritis
Led by University of Guadalajara · Updated on 2026-02-13
46
Participants Needed
2
Research Sites
4 weeks
Total Duration
On this page
Sponsors
U
University of Guadalajara
Lead Sponsor
H
Hospital Civil de Guadalajara
Collaborating Sponsor
AI-Summary
What this Trial Is About
This research aims to determine whether supplementation with vitamin E alpha-tocopherol reduces inflammation and clinical activity in patients with rheumatoid arthritis RA. RA is a common autoimmune disease causing chronic joint inflammation and potential joint damage, which leads to disability and affects quality of life. The study focuses on patients with early RA who have low vitamin E intake and are already receiving standard RA treatments. Participants will be randomly assigned to one of two groups one group will receive conventional synthetic disease-modifying antirheumatic drugs FARMEs plus 800 mg per day of vitamin E, while the other group will receive the same FARMEs plus a 200 mg per day magnesium oxide placebo. The supplementation lasts for one month, with participants taking two capsules daily, one in the morning and one in the afternoon. During the study, participants will attend clinic visits at the start and end of the supplementation period for assessments including clinical activity, blood tests measuring vitamin E levels, inflammatory markers, autoantibodies, and antioxidant capacity. They will keep a diary to track symptoms and supplement intake. Researchers will evaluate changes in vitamin E levels, clinical disease activity DAS-28, pro-inflammatory cytokines, acute phase reactants, and autoantibodies to understand the impact of vitamin E supplementation on RA.
CONDITIONS
Brief Title
"Effect of Vitamin E (α-Tocopherol) on Clinical Activity and Inflammation in Rheumatoid Arthritis"
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Female sex
- Diagnosis of rheumatoid arthritis according to ACR/EULAR 2010 criteria
- Early rheumatoid arthritis for 2 years or less
- Treatment with conventional synthetic FARMEs (Metrotexato, Hydroxychloroquine, Leflunomide, Sulfasalazina, or their combinations)
- Disease Activity Score (DAS28) of 3.2 or higher
- Vitamin E intake less than 15 mg per day
- No other comorbidities
- Age over 18 years
- Voluntary participation with informed consent
You will not qualify if you...
- Liver or kidney disease
- Overlap syndrome
- Coagulation disorders
- Pregnancy
- Use of supplements like iron, vitamin E, or vitamin K in the last three months
- Use of medications such as acetylsalicylic acid, amlodipine, estrogen, glucocorticoids, or drugs for dyslipidemia in the last three months
- Errors in supplement administration
- Adverse effects from the supplement
- Pregnancy during the study
- Insufficient blood sample
- Voluntary withdrawal of consent
Research Team
C
Christian Johana J Baños Hernández, D.Sc.
M
Martin De Leon Cid, B.Nutr.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here